Stocks Health care IMNN

NASDAQ · Health care

Imunon, Inc. (IMNN)

It posted a net loss of $14.7M. In fiscal 2025 capital spending exceeded operating cash flow by $14.2M. At June 30, 2026 it held $6.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.

What Imunon, Inc. does

Imunon, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IMNN.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Imunon, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
2. August 11, 2026
   Executive or director change 8-K
3. August 11, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.54 versus -$2.15.
4. August 11, 2026
   Quarterly results 8-K
5. June 30, 2026
   Executive or director change 8-K
6. June 17, 2026
   Employee stock plan registration S-8
7. June 16, 2026
   Executive or director change 8-K
8. June 4, 2026
   Material agreement 8-K
9. May 15, 2026
   Passive stake changed SCHEDULE 13G/A
10. May 12, 2026
    Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.84 versus -$3.15.

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 15, 2026. Insider transactions on SEC

Insider trades

What the people running Imunon, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $3.9K worth of shares in the last 90 days and bought none on the open market.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns IMNN

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

4 insiders reported holding 245,463 shares in total, about $346.1K at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about IMNN

What does Imunon, Inc. do?

Imunon, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IMNN.

Is Imunon, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $14.7M.

When did Imunon, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 15, 2026.

Similar companies

Compare IMNN with

Compare IMNN with any company

Follow IMNN

Get an email when Imunon, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow IMNN: get an email when it files

Where the numbers come from

Financial figures are the values Imunon, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.